Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 10:30 a.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2017
Reports Net Revenues of $57.9 Million for the Three Months Ended September 30, 2017
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2017
RANCHO CUCAMONGA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2017, ended September 30, 2017, after the market closes on Wednesday, November 8, 2017, and will hold a conference call
View HTML
Toggle Summary Amphastar Announces Approval for Neostigmine Methylsulfate Injection, USP
RANCHO CUCAMONGA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application (ANDA) for Neostigmine Methylsulfate Injection, USP, 1mg/mL, 10mL, and
View HTML
Toggle Summary Amphastar Pharmaceuticals Receives FDA Approval for Sodium Bicarbonate Injection
RANCHO CUCAMONGA, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on September 19, 2017, the U.S. Food and Drug Administration ("FDA") granted approval of the company's abbreviated new drug application ("ANDA") for Sodium Bicarbonate injection
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the 2017 Wells Fargo Securities Healthcare Conference
RANCHO CUCAMONGA, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2017 Wells Fargo Securities Healthcare Conference on Wednesday, September 6, 2017 at 1:50 p.m.
View HTML
Toggle Summary Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2017
Reports Net Revenues of $65.2 Million for the Three Months Ended June 30, 2017
View HTML
Toggle Summary Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9, 2017
RANCHO CUCAMONGA, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2017, ended June 30, 2017, after the market closes on Wednesday, August 9, 2017, and will hold a conference call to
View HTML
Toggle Summary Amphastar Announces Jury Verdict in Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
RANCHO CUCAMONGA, Calif., July 24, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that a federal jury delivered a unanimous verdict in favor of Amphastar in a lawsuit brought by Momenta Pharmaceuticals, Inc. and Sandoz Inc. (the "Plaintiffs") in the U.S.
View HTML
Toggle Summary Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, will be presenting at the Jefferies Global Healthcare Conference on Tuesday, June 6, 2017 at 10:00 a.m. Eastern Time in New York, NY.
View HTML

 

Copyright ©2018 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States